NCT02722408: A trial that was reported late by NeuroBo Pharmaceuticals Inc.
This trial has reported, although it was 765 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02722408 |
|---|---|
| Title | A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 30, 2016 |
| Completion date | April 30, 2017 |
| Required reporting date | April 30, 2018, midnight |
| Actual reporting date | June 3, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 765 |